CO-LIQID
30.5.2022 08:32:07 CEST | Business Wire | Press release
Liqid , the world’s leading software company delivering data center composability, announced today it is taking part in ISC High Performance 2022 (booth #B211), providing live demonstrations of the company’s Liqid Matrix™ composable disaggregated infrastructure (CDI) software. Dynamic infrastructure orchestration from Liqid delivers improved IT performance and agility for the most demanding next-gen applications such as artificial intelligence and machine learning (AI+ML), edge computing deployments, high-performance computing, and virtualization. Increased efficiency helps minimize the data center footprint, delivering software-defined ability to share resources no matter where they physically reside, making Liqid solutions fundamental to a more sustainable data center ecosystem. Available today for customers in the Europe, Middle East, & Africa (EMEA) region, solutions based on Liqid Matrix CDI software deliver architectural flexibility and efficiency to maximize time-to-value for high-value applications across industry verticals.
“AI applications, edge data center deployments reading multiple streams of sensor data, HPC-driven genomic research, and even more traditional software deployments like virtualization are taxing traditional data center infrastructures, increasingly making them neither practical nor sustainable,” said Paul Silver, Vice President and General Manager, EMEA, Liqid. “We’re excited to be able to bring our composable solutions to ISC High Performance attendees and the wider EMEA market to help better address the sea changes taking place in the data center ecosystems.”
Liqid Matrix software enables IT users to configure bare-metal servers in seconds. With Liqid Matrix, independent resource pools are orchestrated on-demand to instantly address the requirements of the specific workload. Once the workload is complete, resources are released back into the pool for use by other applications. This eliminates the need for costly overprovisioning of infrastructure, reduces power and cooling requirements, and enables the most efficient and sustainable data center architectures.
Liqid offers EMEA customers a cost-effective way to disaggregate and pool data center resources at large scale via software, across all industry-standard fabrics, for dynamically configurable, bare-metal servers. With composable disaggregated infrastructure solutions from Liqid, IT users can:
- Accelerate Time-to-Value: Dynamically configure servers in seconds to meet exacting workload requirements. Create configurations that aggregate the power of dozens of GPUs and other accelerators as required.
- Improve IT Agility: Scale resources like compute, networking, NVMe storage, GPU, FPGA, and storage-class memory beyond a server’s physical limitations, across all industry-standard fabrics, with just a couple of clicks; when data center devices are no longer needed, they are released back to the pool to be used by other applications. Leverage Liqid Command Center’s RESTful API and integrations with popular tools like Ansible to automate the provisioning of bare‐metal resources.
- Increase Efficiency: Only purchase resources when they’re needed. Extend the life cycle of existing IT server investments. Better manage costs associated with data center footprint with greater infrastructure utilization.
“Liqid is a company that offers a flexible, software-defined infrastructure designed to optimize the access and usage of high-value IT components. Liqid has worked to create what it called ‘composable disaggregated infrastructure’ that frees IT users from vendor lock-in and traditional purchasing cycles, enabling them to build a living data center architecture that changes to meet their business needs and scales as required,” wrote senior analyst Scott Sinclair and senior research analyst Moya Keane of Enterprise Strategy Group (ESG), a division of TechTarget, in a recent ESG Showcase . “A composable infrastructure provides significant improvements to performance, architectural optimization, hardware utilization issues, and, importantly, footprint efficiency—basically eliminating the urge to overprovision.”
To download ESG’s “Why IT Must Prioritize Sustainability,” go here . Schedule an appointment with an expert on solutions based on Liqid Matrix CDI software and set up a free infrastructure evaluation by going here. Follow Liqid on Twitter and LinkedIn to stay up to date with the latest Liqid news and industry insights.
About Liqid
Liqid’s composable infrastructure software platform, Liqid Matrix, unlocks cloud-like speed and flexibility plus higher efficiency from on-prem infrastructure. Now IT can configure, deploy, and scale physical, bare-metal servers in seconds, then reallocate valuable accelerator and storage resources via software as needs evolve. Dynamically provision previously impossible systems or scale existing investments, and then redeploy resources where needed in real-time. Unlock cloud-like datacenter agility at any scale and experience new levels of resource and operational efficiency with Liqid.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005033/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom